PL EN


2006 | 2/2006 (12) | 61-79
Article title

Interwencjonizm państwowy a dostępność opieki zdrowotnej

Content
Title variants
EN
State Interventionism and Accessibility of Health Care
Languages of publication
PL EN
Abstracts
PL
Efektywność współpracy uczestników łańcucha dostaw leków jest wyrażona poziomem dostępności leków w poszczególnych krajach. Macierzowy układ zależności podmiotów wpływających na zaspokojenie potrzeb konsumenta wskazuje na jakość dobieranych narzędzi polityki handlowej państwa jako determinant poziomu zdrowia obywateli. Jednocześnie, wobec tracących na znaczeniu środków taryfowych, kluczowego znaczenia dla ochrony rodzimego rynku nabierają niezharmonizowane regulacje administracyjno-prawne. Podczas gdy określenie i wprowadzenie dyrektyw jest relatywnie proste, to egzekwowanie ich realizacji na szczeblu administracyjnym wymaga skonstruowania równie efektywnych procedur wykonawczych. W przeciwnym wypadku zaspokojenie potrzeb pacjenta, czy to lekiem zagranicznym, czy też krajowym, może być utrudnione. Jakość zdrowia społeczeństwa, a zatem jego produktywność, związana jest nie tylko z poziomem rozwoju gospodarczego danego państwa, lecz także z efektywnością obowiązujących regulacji administracyjno-prawnych. Tworzona jest swoista spirala zależności, w której główną rolę zdaje się odgrywać umiejętność doboru instrumentów polityki handlowej zapewniających wysoki poziom dostępu do najnowszych farmakoterapii bez szkody dla rozwoju rodzimego przemysłu, a wręcz stymulując go.
EN
The efficiency of cooperation between the members in a medicine supply chain is expressed by the level of accessibility of medicines in particular countries. The metrix system of dependency of the subjects having impact on fulfilling customer's needs points to the quality of the tools of trading policy selected by the state as a determiner of the ratio of well-being of its citizens. Also, due to the decreasing importance of charging measures, key significance for protecting the domestic market is attributed to not harmonized administrative and legal regulations. While it is relatively simple to draw and introduce a directive, enforcing its implementation on the administrative level requires developing equally effective executory procedures. Otherwise, fulfilling patient's needs with either foreign or domestric medicine can be impeded substantially. The quality of social health, and therefore the productiveness of a society, is not related merely to the range of economic develoment of given country, but also to the effectiveness of the administrative and legal regulations in force. A specific spiral of interdependencies is created, where the major role seems to be attributed to the skill of selecting the instruments of trading policy ensuring high level of access to state-of-the-art pharmacotherapies without a loss for the development of domestic industry, but with a provision of certain stimuli for it.
Keywords
Year
Issue
Pages
61-79
Physical description
Dates
published
2006-06-15
Contributors
References
  • Alliance for Retired Americans Organization. 2003. Prescription Drugs, Washington: Alliance for Retired Americans, www.retiredamericans.org.
  • Artykuł 66.1 i 70.9 porozumienia WTO TRIPs.
  • Australian Industry Commission. 1996. The Pharmaceutical Industry, Melbourne: Australian Govemment Publishing Service.
  • Baker, B. 2004. Processes and Issues for Improving Access to Medicines. Willingness and Ability to Utilize TRIPS Flexibilities in Non-Producing Countries, London: DFID Health System Resource Centre.
  • Bale, H. 2001. Consumption and Trade in Off-Patented Medicines, Working Paper, nr WG 4:3, Geneva: WHO, Commission on Macroeconomic and Health.
  • Bennett, S., Quick, J. i G. Velasques. 1997. Public-Private Roles in the Pharmaceutical Sector: Implications for equitable access and rational drug use, Geneva: WHO.
  • Cambridge Pharma Consultancy. 2002. Delays To Market Access In Europe, Cambridge: Cambridge Pharma Consultancy.
  • Cao, A.O. 1980. Non-tariff Barriers to U. S. Manufactured Exports. Columbia Journal of World Business, Summer 1980.
  • Conlin, L. 2001. Using Trade Promotion Authority to Reduce Non-Tariff Barriers, Export America, September 2001.
  • Correra, C. 2002. Implementations of the Doha Declaration on the TRIPs Agreement and Public Health, Geneva: WHO.
  • Dukes, M., Haaijer-Ruskamp, F., de Joncheere, C. i A. Rierveld. 2003. Drugs and Money: Prices, Affordability and Cost Containment, Geneva: WHO.
  • EFPIA. 2005. The Pharmaceutical Industry in Figures. Key Data, 2005 Update, Brussels: EFPIA.
  • Ernst & Young. 2004. Time for Checkup: Trade Issues In Heath Sciences, Davos: World Economic Forum 2004.
  • European Commission. 2003. Working document on developing countries duties and taxes on essential medicines used in the treatment of major communicable diseases, Brussels: European Commission.
  • Kanavos, P. 2002. EU pharmaceutical Policy. The challenges and opportunities of enlargement w: Eurohealth Vol. 8 no 4 Autum 2002.
  • Kondrat, M. 2003. Import równoległy leków. Gazeta Prawna -Biznes i Prawo nr 57 (913), 21-23 marca.
  • Krasovec, K. i C. Connor. 1998. Survey on Tax Treatment of Public Health Commodities. Technical Report no. 17, Partnership for Health Reform Project, Bethesda : Abt Associates Inc.
  • Levison, L. 2003. Policy and programming options for reducing the procurement costs of essential medicines in developing countries, Boston: Boston University School of Public Health.
  • Mossialos, E., Mrazek, M. i T. Walley. 2004. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality, Berkshire: Open University Press.
  • Ratanawijitrasin, S. i E. Wondemagegnehu. 2002. Effective Drug Regulation: a Multicountry Study, Geneva: WHO.
  • Schiavo-Campo, S. 1999. Simplification of Customs Procedures: reducing transaction costs for efficiency, integrity and trade facilitation, Asian Development Bank.
  • Shaw, R. i A. Elmendorf. 1994. Better health in Africa, Washington: The International Bank for Reconstruction and Development/ The World Bank.
  • WHO. 1946. Constitution of the World Health Organization, New York, Geneva.
  • WHO. 1998. Selected Topics in Health Reform and Drug Financing, WHO Action Program on Essential Drugs, Geneva: WHO.
  • WHO. 2000a. The World Heath Report 2000. Health Systems: Improving Performance, Geneva: WHO.
  • WHO. 2000b. WHO Medicines Strategy 2000-2003: Framework for Action In Essentials Drugs and Medicines Policy, Geneva: WHO.
  • WHO. 2005. Pharmaceutical Tariffs: What is their effect on prices, protection of local industry and revenue generation? Geneva: WHO Secretariat for Commission on Intellectual Property Rights, Innovation and Public Health.
  • WHO-WTO. 2001. More equitable pricing for essential drugs: what do we mean and what are the issues? Geneva: WHO Secretariat.
  • Woodward, D. 2001. Trade Barriers and Prices of Essential Health Sector Inputs, New Delhi: Indian Council for Research on International Economics Relations.
  • World Bank. 1994. Towards Better Health in Sub Saharan Africa. Findings, nr 25.
Document Type
Publication order reference
Identifiers
ISSN
1644-9584
YADDA identifier
bwmeta1.element.desklight-233c6e09-a163-4392-a425-c4b7fbea1946
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.